← Leaderboards
Boyko S Atanassov
Roswell Park Cancer Institute Corp
$1,250,312
Attributed
$1,250,312
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $437.8K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,250,312 · 1
By mechanism
R01$1,250,312 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Jee Eun Choi$120,842
- Maria R Baer$1,593,414
- Maria L Avantaggiati$6,905,214
- Xiang-Yang Wang$11,998,946
Others in their field
Other Rising Stars on “Acceleration”
- Angee Greer · Ppd Development Lp$82,531,927
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Nancy Jean Sullivan · Boston University Medical Campus$23,000,000
- Alanna Maguire · Mayo Clinic Rochester$16,353,346
- Michael Hogarth · University Of California, San Diego$15,375,743
Research focus
AccelerationAffectAllelesAntibody-Drug ConjugatesBiochemicalBreast Cancer CellBreast Cancer Cell LineBreast Cancer PatientCancer CellCancer Cell LineCancer ModelCancer PatientCancer SurvivalCdk4 GeneCell GrowthCell LineCell ProliferationCellsClinically RelevantCrispr/Cas TechnologyCyclin D1DedicationsDeubiquitinating EnzymeAblation
Grant awards (3)
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer$437,784
R01 · FY2025 · CA · contact PI
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer$412,284
R01 · FY2024 · CA · contact PI
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer$400,244
R01 · FY2023 · CA · contact PI